17:40 , Sep 28, 2018 |  BC Week In Review  |  Financial News

AI diagnostic company IDx raises $33M venture round

AI diagnostic company IDx LLC (Coralville, Iowa) raised $33 million in a venture financing on Sept. 26 led by 8VC, with participation from Optum Ventures, Alpha Edison and Heritage Provider Network. In April, FDA approved...
16:36 , Jan 12, 2018 |  BC Week In Review  |  Financial News

Neural Analytics raises $15M B round

Medical device company Neural Analytics Inc. (Los Angeles, Calif.) raised $15 million on Jan. 8 in a series B round led by Alpha Edison. In October 2017, the U.S. Army Medical Research and Material Command...
23:53 , Sep 21, 2017 |  BC Extra  |  Clinical News

Akari gains on Phase III PNH plans for C5 inhibitor

Akari Therapeutics plc (NASDAQ:AKTX) gained $3.15 (56%) to $8.74 on Thursday after the company announced plans to start Phase III testing in 1Q18 of lead candidate Coversin to treat paroxysmal nocturnal hemoglobinuria. The announcement appears...
23:31 , May 17, 2017 |  BC Extra  |  Company News

Management tracks

Protein therapeutics company Molecular Partners AG (SIX:MOLN) named Patrick Amstutz CEO. Amstutz had been acting CEO since the November 2016 resignation of Christian Zahnd. Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) said CEO...
17:57 , Apr 28, 2017 |  BC Week In Review  |  Clinical News

Tenofovir exalidex: Interim Ph IIa data

Interim data from 12 treatment-naïve patients with HBV infection in an open-label, Thai Phase IIa trial showed that once-daily 100 mg oral tenofovir exalidex led to a lower mean HBV viral load after 21 days...
07:00 , Oct 13, 2016 |  BC Innovations  |  Product R&D

Elastic bones

A group at Northwestern University has created a "hyperelastic bone" scaffold to address the need for a bone-inducing material that is easily manufactured, low cost and easy to manipulate during surgery. While the short-term goal...
07:00 , Aug 25, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Rats and dogs treated with potassium channel Kir1.1 (KCNJ1) inhibitor as models of rare genetic disease Bartter syndrome

Disease models TECHNOLOGY: Animal models Rats and dogs treated with a KCNJ1 inhibitor could be used to screen therapies for Bartter syndrome, a genetic disease involving low potassium levels and consequent cardiovascular and renal symptoms....
07:00 , Jun 27, 2016 |  BC Week In Review  |  Company News

UCLA, Bone Biologics deal

UCLA granted Bone Biologics an option to license exclusive, worldwide rights to use NEL-like protein 1 (NELL1) to treat osteoporosis. Bone Biologics is funding development of a NELL1-based product to treat bone regeneration in spinal...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Financial News

Bone Biologics completes private placement of convertible notes

Bone Biologics Corp. (OTCQB:BBLG), Edison, N.J.   Business: Musculoskeletal   Date completed: 2016-02-29   Type: Private placement of convertible notes   Raised: $2 million   Shares outstanding prior: 33.3 million   Investor: Hankey Capital  ...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Financial News

Bone Biologics completes private placement

Bone Biologics Corp. (OTCQB:BBLG), Edison, N.J.   Business: Musculoskeletal   Date completed: 2016-02-29   Type: Private placement   Raised: $2.5 million   Shares: 1.2 million   Price: $2.05   Shares after offering: 33.3 million  ...